X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (14) 14
oncology (14) 14
cancer (13) 13
tumors (12) 12
humans (11) 11
female (9) 9
middle aged (9) 9
aged (8) 8
analysis (8) 8
care and treatment (8) 8
male (8) 8
carcinoma (7) 7
lung cancer (7) 7
metastasis (7) 7
adult (6) 6
aged, 80 and over (6) 6
cancer therapies (6) 6
chemotherapy (6) 6
medical prognosis (6) 6
melanoma (6) 6
antineoplastic agents - therapeutic use (5) 5
expression (5) 5
mutation (5) 5
patients (5) 5
survival (5) 5
antimitotic agents (4) 4
antineoplastic agents (4) 4
biomarkers (4) 4
gene expression (4) 4
genetic aspects (4) 4
immunotherapy (4) 4
proteins (4) 4
resistance (4) 4
therapy (4) 4
treatment outcome (4) 4
abridged index medicus (3) 3
biomarkers, tumor - blood (3) 3
bladder cancer (3) 3
cell line, tumor (3) 3
clear cell-type renal cell carcinoma (3) 3
clinical trials (3) 3
colon cancer (3) 3
cytotoxicity (3) 3
growth-factor (3) 3
laboratories (3) 3
lung neoplasms - pathology (3) 3
lung-cancer (3) 3
mice (3) 3
monoclonal antibodies (3) 3
multidisciplinary sciences (3) 3
neoplasm metastasis (3) 3
nivolumab (3) 3
prognosis (3) 3
research (3) 3
research article (3) 3
toxicity (3) 3
tumor (3) 3
urologic neoplasms - drug therapy (3) 3
adenocarcinoma (2) 2
adenocarcinoma - drug therapy (2) 2
animals (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
apoptosis (2) 2
bioindicators (2) 2
biology (2) 2
bladder-cancer (2) 2
blockade (2) 2
carboplatin - administration & dosage (2) 2
carcinoma, non-small-cell lung - diagnostic imaging (2) 2
carcinoma, non-small-cell lung - drug therapy (2) 2
carcinoma, non-small-cell lung - genetics (2) 2
carcinoma, transitional cell - drug therapy (2) 2
carcinoma, transitional cell - secondary (2) 2
cell lines (2) 2
cell migration (2) 2
cisplatin (2) 2
cisplatin - administration & dosage (2) 2
clinical medicine (2) 2
colon (2) 2
colorectal cancer (2) 2
colorectal-cancer (2) 2
cytokines (2) 2
dendritic cells (2) 2
diagnosis (2) 2
disease progression (2) 2
disease-free survival (2) 2
double-blind (2) 2
drug resistance, neoplasm - genetics (2) 2
effectiveness (2) 2
erlotinib (2) 2
exons (2) 2
gefitinib (2) 2
gemcitabine (2) 2
gene-mutations (2) 2
genes (2) 2
genomes (2) 2
immunology (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10031, pp. 1909 - 1920
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10064, pp. 67 - 76
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 672,681a - 681,681a
Journal Article
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 11/2014, Volume 41, Issue 11, pp. 2058 - 2065
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2014, Volume 9, Issue 1, p. e86263
Purpose: To identify tissue microRNAs predictive of sunitinib activity in patients with metastatic renal-cell-carcinoma (MRCC) and to evaluate in vitro their... 
SURVIVAL | INTERFERON | CANCER-PATIENTS | ASSOCIATIONS | 1ST-LINE SUNITINIB | MULTIDISCIPLINARY SCIENCES | MATRIX-METALLOPROTEINASE-9 | TARGETS | SELECTION | EXPRESSION | PROGRESSION | Kidney Neoplasms - genetics | Prognosis | Humans | Middle Aged | Carcinoma, Renal Cell - genetics | Male | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Vascular Endothelial Growth Factor A - secretion | Neoplasm Metastasis | Aged, 80 and over | Adult | Female | Indoles - pharmacology | Matrix Metalloproteinase 9 - secretion | Antineoplastic Agents - pharmacology | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Reproducibility of Results | Paracrine Communication | Carcinoma, Renal Cell - pathology | Treatment Outcome | Kidney Neoplasms - mortality | Carcinoma, Renal Cell - mortality | Drug Resistance, Neoplasm - genetics | Pyrroles - pharmacology | Models, Biological | Cell Line, Tumor | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | MicroRNAs - genetics | Kidney Neoplasms - drug therapy | Antimitotic agents | Care and treatment | MicroRNA | Carcinoma | Analysis | Metastasis | Antineoplastic agents | Vascular endothelial growth factor | Cancer | Cell survival | Effectiveness | Secretion | MiRNA | Paracrine signalling | Oncology | Gene expression | Cancer therapies | Patients | Gelatinase B | Metastases | MicroRNAs | Medical prognosis | Predictions | Biomarkers | Prostate cancer | Bioinformatics | Cell migration | Clear cell-type renal cell carcinoma | Tumors | Kidney transplantation | Phenotype | RNA | Fenotip | Renal cancer | Càncer de ronyó | Resistència als medicaments | Marcadors bioquímics | Micro RNAs | Drug resistance | Biochemical markers
Journal Article
International Journal of Cancer, ISSN 0020-7136, 10/2019, Volume 145, Issue 7, pp. 1991 - 2001
Journal Article
Cancer Medicine, ISSN 2045-7634, 07/2018, Volume 7, Issue 7, pp. 3474 - 3483
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 01/2017, Volume 127, Issue 1, pp. 153 - 168
Most patients who initially respond to treatment with the multi-tyrosine kinase inhibitor sunitinib eventually relapse. Therefore, developing a deeper... 
MEDICINE, RESEARCH & EXPERIMENTAL | TARGETING MCL-1 | DOSE-ESCALATION | APOPTOSIS | THERAPY | RESISTANCE | TUMOR | TYROSINE KINASE INHIBITOR | ANTITUMOR-ACTIVITY | CANCER | RENAL-CELL CARCINOMA | Neoplasms - metabolism | TOR Serine-Threonine Kinases - metabolism | Humans | Myeloid Cell Leukemia Sequence 1 Protein - metabolism | Glycogen Synthase Kinase 3 beta - genetics | Multiprotein Complexes - genetics | Mechanistic Target of Rapamycin Complex 1 | Multiprotein Complexes - metabolism | Sunitinib | MAP Kinase Signaling System - genetics | TOR Serine-Threonine Kinases - genetics | Neoplasms - genetics | Indoles - pharmacology | Enzyme Stability | Glycogen Synthase Kinase 3 beta - metabolism | Myeloid Cell Leukemia Sequence 1 Protein - genetics | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Pyrroles - pharmacology | Animals | MAP Kinase Signaling System - drug effects | Mice, Nude | Cell Line, Tumor | Mice, Inbred NOD | Mice | Neoplasms - pathology | Drug Resistance, Neoplasm - drug effects | Care and treatment | Carcinoma, Renal cell | Gene expression | Analysis | Medical research | Phosphorylation | Laboratories | Melanoma | Cytotoxicity | Kinases | Experiments | Autophagy | Cancer therapies | Patients | Proteins | Cell growth | Bone cancer | Regulation | Drug dosages | Tumors | Apoptosis | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
The Oncologist, ISSN 1083-7159, 06/2011, Volume 16, Issue 6, pp. 877 - 885
Journal Article